Avedro receives approval in China for KXL cross-linking system

Avedro has received approval from the China Food and Drug Administration for its KXL cross-linking system for the treatment of keratoconus and post-LASIK ectasia, according to a company press release. The approval of the KXL system is the result of a multi-year effort by Avedro and its China distributor, Shinesee (Fujian) Ophthalmic Technology Development.